Please assess the completion status of the following clinical trial:

Trial Title: Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* Histological or cytological diagnosis of AOC~* Stable disease (SD) or progression at time of study entry Recurrent or progressive AOC ≥ 90 days of duration of response for first-line therapy~* Measurable disease defined by RECIST criteria~* ECOG Performance Status of 0, 1, or 2~* Life expectancy \> 3 months~* Adequate bone marrow, Renal, Hepatic reserve:~  * absolute neutrophil (segmented and bands) count (ANC) ≥ 1500 cells/μL~ * platelet count ≥ 100,000 cells/μL~ * hemoglobin ≥ 9 g/dL~ * Total bilirubin ≤ 1.5 X ULN~ * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.0 X ULN~ * Alkaline Phosphatase (ALP) ≤ 2.0 X ULN~ * Serum creatinine \< 1.5mg/dL or calculated creatinine clearance \> 60mL/min~* Signed a written informed consent~Exclusion Criteria:~* Active infection~* Symptomatic brain lesion~* Any other type of cancer during the previous 5 years except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix Severe concurrent diseases~* Prior anticancer therapy within 4 weeks before enroll~* Active pregnancy test and Pregnant or nursing women~* Participation in any investigational drug study within 28 days prior to study entry

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Topotecan (Type: ACTIVE_COMPARATOR): Topotecan
- Camtobell (Type: ACTIVE_COMPARATOR): Belotecan

Based on this trial design, predict the completion outcome and termination type (if applicable).